Legal entity

Novo Nordisk

Company NVO

Of the tracked stories, 2 of 4 also mention Eli Lilly, the most common co-covered peer. The 135-day window averages about 0.2 stories each week. The busiest single day carried 2. They are less corroborated than the beat average, carrying 3 original sources each against 3.5 for the same window.

Last mentioned: 1d ago

Entity pulse

Recent coverage · Novo Nordisk

4 stories
6.5 avg impact
25% positive
50% negative

Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 25 percentage points.

  • 25% positive
  • 25% neutral
  • 50% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Novo Nordisk

Of the tracked stories, 2 of 4 also mention Eli Lilly, the most common co-covered peer. The 135-day window averages about 0.2 stories each week. The busiest single day carried 2. They are less corroborated than the beat average, carrying 3 original sources each against 3.5 for the same window. corporate-law accounts for 2 of the 4 tracked stories, while 2 other categories carry the remainder. Their average consequence score of 6.5 sits level with the 6.5 recorded across the beat in that window. We currently track 4 Legal stories that mention Novo Nordisk, published between March 9, 2026 and July 21, 2026.

Stories tracked
4
Per week
0.2
Sources per story
3

Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 1177 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Novo Nordisk. Shared-story counts are live from our verified record — not editorial picks.

Key Data

ticker
NVO
name
Novo Nordisk
price
135.75
change
-2.15
changePct
-1.56

Timeline

  1. Lawsuit Filed

    Novo Nordisk sues Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising and unfair competition under the Lanham Act.

  2. Cease-and-desist letter

    Novo Nordisk sends a formal request to Eli Lilly to stop running or correct certain ads.

  3. Settlement & Collaboration

    Hims & Hers and Novo Nordisk announce the end of litigation and the start of a commercial partnership.

  4. Settlement Reached

    Hims & Hers agrees to stop selling compounded GLP-1s to resolve legal disputes.

  5. FDA Approves Wegovy 7.2 mg

    Novo Nordisk receives U.S. approval for a higher-dose semaglutide injection for obesity, backed by the STEP UP trial showing 19% average weight loss.

  6. High-dose Wegovy approved

    Novo Nordisk’s high-dose obesity injection enters the market, achieving weight loss more comparable to Zepbound.

  7. Supply Stabilization

    FDA indicates that semaglutide shortages are easing, increasing legal pressure on compounders.

  8. Litigation Surge

    Novo Nordisk and Eli Lilly file multiple lawsuits against compounding pharmacies and telehealth firms.

  9. FDA Shortage Updates

    FDA begins removing specific GLP-1 dosages from the national shortage list.

  10. Hims & Hers GLP-1 Launch

    Hims & Hers announces the launch of compounded GLP-1 injections at a significant discount to brand names.

  11. HIMS Launches GLP-1s

    Hims & Hers enters the weight-loss market with compounded GLP-1 offerings.

  12. Litigation Wave Begins

    Novo Nordisk starts filing lawsuits against medical spas and pharmacies over compounded semaglutide.

Stories mentioning Novo Nordisk 4

Novo Nordisk is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.